India’s Sun Pharmaceuticals, which is working hard to shift its focus from generic to novel and specialty drugs, has won FDA approval of a new treatment for glaucoma. The drug will be made at Sun’s once-troubled Halol plant, indicating that
read moreAbout a year after getting Calquence approved in mantle cell lymphoma, AstraZeneca has pulled off its second blood cancer nod in a novel antibody drug with peak sales estimated at $500 million. More: In a blood cancer win, AstraZeneca nabs
read moreMedical Science Liaison of the Year has been expanded to include three levels of seniority and forms the backbone of the all new Medical and Scientific Excellence Awards, alongside categories for scientific advisors and medical information professionals. More: It’s an
read moreViiV Healthcare has submitted an application in Europe for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection. More: ViiV submits two-drug regimen for HIV in Europe Source: News
read moreAlarm bells over the NHS’ ability to cope with looming winter pressures are ringing again after some aspects of service performance sunk to new lows in the summer, with record waiting times for A&E and cancer treatment. More: NHS summer
read moreA Takeda founding family member has gone public with his opposition to the Shire purchase, but that doesn’t stop the company from planning for a successful deal as it moves its U.S. headquarters closer to Shire’s operations; Sanofi is creating
read more© 1994 - 2026 B.M. Pharmaceuticals